Non-small Cell Lung Cancer research hub
50 indexed studies · 25 currently recruiting
- active not recruitingPHASE2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
This study is looking at new combinations of medicines for advanced lung cancer that has spread. It combines a drug called sacituzumab govitecan (SG) with pembrolizumab, and sometimes with chemotherapy agents like carboplatin or cisplatin, to see how well they work together.
United States · Australia · Canada - recruitingPHASE3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
This study compares two treatments for early-stage lung cancer: special radiation (SAbR) and a smaller surgery (sublobar resection). It aims to see if SAbR helps people live longer and healthier, especially those who might find full surgery too risky.
United States · Australia · Canada - recruitingPHASE3
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
This study looks at a new drug, gotistobart, for advanced non-small cell lung cancer that has worsened after previous PD-1/PD-L1 treatment. It compares gotistobart to standard chemotherapy (docetaxel) to see if it can help people live longer.
United States · Australia · Belgium - authorisedTherapeutic exploratory (Phase II)
IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease
This study looks at new ways to treat advanced lung cancer in people who also have a lung condition called Interstitial Lung Disease. It checks how well new treatments work and if they cause any breathing problems, aiming to find safer, more effective options.
France - authorisedTherapeutic exploratory (Phase II)
A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
This study is looking at new combinations of medicines for advanced non-small cell lung cancer. Researchers want to see if these combinations are safe, how they work in the body, and if they can shrink tumours. It's a key step in finding better treatments for this type of cancer.
France · Italy · Spain - recruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
United States · Argentina · Belgium - active not recruitingPHASE1, PHASE2
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This study is testing a new discovery drug called RO7247669 for advanced cancers. It aims to find the safest and most effective dose, and see if it can shrink certain tumours like melanoma, lung, and oesophageal cancer. The drug works by boosting the body's own immune system to fight cancer.
Denmark · Georgia · Israel - active not recruitingPHASE2
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
This study uses a special scan called a PET/CT with a medicine called zirconium Zr 89 crefmirlimab berdoxam. It’s for people with advanced melanoma, Merkel cell cancer, kidney cancer, or lung cancer. We want to see if this scan can help predict how well immunotherapy will work for their cancer.
United States · Australia · Belgium - authorisedTherapeutic confirmatory (Phase III)
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
This study is comparing a new medicine called Pumitamig with a standard treatment, Pembrolizumab, for a type of lung cancer. Researchers want to see if Pumitamig can stop cancer from growing for longer or help people live longer than current treatment.
Portugal · Norway · Sweden - active not recruitingPHASE3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
This study compares two medicines, X-396 (ensartinib) and crizotinib, for people with a specific type of lung cancer called ALK-positive non-small cell lung cancer. It looks at how well each medicine works and if they are safe.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This study looks at a new drug, selpercatinib, for advanced cancers, including certain lung, thyroid, and other solid tumours that have a specific genetic change called a RET alteration. Researchers want to check its safety, how it works in the body, and if it helps shrink tumours.
United States · Australia · Canada - recruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
United States · Argentina · Australia - active not recruiting
TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)
This study looks at how lung cancer changes over time and with treatment. By studying cancer samples from patients, researchers hope to better understand why some cancers come back after treatment and how to improve care for people with non-small cell lung cancer.
United Kingdom - recruitingPHASE3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
This study looks at new drug combinations (Dato-DXd with rilvegostomig) for a type of advanced lung cancer. It compares them to a standard treatment, pembrolizumab, to see if they work better and are safe as a first treatment option.
United States · Australia · Austria - recruiting
Cardiopulmonary Toxicity of Thoracic Radiotherapy
This study looks at how radiotherapy for lung and oesophageal cancer might affect your heart and lungs. We want to see if a condition called pulmonary hypertension, which affects blood flow in the lungs, is a common side effect so we can improve care.
Belgium · Netherlands · United Kingdom - recruitingPHASE3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
This study is looking at extra treatment with a drug called durvalumab after surgery for certain early-stage lung cancers. It aims to see if this additional medicine helps people stay cancer-free for longer after initial chemotherapy and surgery.
Australia · Austria · Belgium - active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
United States · Australia · Brazil - active not recruitingPHASE3
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study compares a new drug, DS-1062a, with a standard chemotherapy, docetaxel, for advanced lung cancer. It's for people whose cancer has grown after previous treatments. We want to see if DS-1062a is safer and works better.
United States · Argentina · Australia - recruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
United States · Argentina · Australia - active not recruitingPHASE1
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
This study looks at combining two medicines, Guadecitabine/ASTX727 and Pembrolizumab, for people with advanced solid tumours, including a type of lung cancer. The main aim is to check if this new combination is safe and what doses work best.
United Kingdom - recruiting
Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer
This study looks at how easy it is to collect blood and lung cancer tissue samples from two groups of patients. The goal is to better understand lung cancer and help develop new, more effective treatments, especially for those with specific genetic changes.
United Kingdom - recruiting
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
This study looks at whether we can find signs of non-bowel cancers, like lung or pancreatic cancer, in a small sample of mucus taken from a person's bottom. We're testing a new, simple device to see if it can help detect these cancers earlier.
United Kingdom - active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This study looks at new ways to treat a type of lung cancer before surgery. We're testing a drug called osimertinib, either alone or with chemotherapy, against chemotherapy by itself. The goal is to see if these new treatments can help more people with resectable non-small cell lung cancer.
United States · Austria · Brazil - recruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
United States · Argentina · Austria - recruitingPHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This study looks at a new drug, BNT116, for advanced lung cancer. It explores if BNT116 is safe, how much to give, and how well it works when used alone or with other treatments for different types of non-small cell lung cancer.
United States · Australia · Germany - active not recruitingPHASE1
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is testing a new cancer medicine, botensilimab, sometimes with another drug, balstilimab. It's for people with advanced cancers that haven't responded to other treatments. Doctors want to see if it's safe, how it works, and find the best dose.
United States · United Kingdom - active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
United States · Australia · Belgium - recruitingPHASE3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
This study looks at two different drug treatments for advanced non-small cell lung cancer. It compares a new drug called ivonescimab with a standard treatment, pembrolizumab, both given with chemotherapy. The aim is to see which treatment works better and is safer.
United States · Belgium · Canada - active not recruitingPHASE1
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
This study looks at a new drug, Amivantamab, alone or with other treatments, for certain types of advanced lung cancer. We want to find the safest and most effective dose, and see how well it works.
United States · Australia · Canada - active not recruitingPHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations to treat advanced lung cancer. It compares two different drug mixes, each including chemotherapy, to see which works best and is safest for people with Stage IV or recurrent non-small cell lung cancer.
United States · Argentina · Australia - recruitingPHASE3
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
This study looks at treating brain tumours from melanoma or lung cancer. It compares standard treatments (like immunotherapy) plus focused radiation to standard treatments alone, aiming to find the best way to improve lives and reduce side effects.
Italy · Netherlands · Spain - active not recruitingPHASE1
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This study is testing a new drug, PF-08046049/SGN-BB228, for advanced melanoma and other difficult-to-treat solid cancers. It aims to find a safe dose and see how well it works, as well as checking for side effects.
United States · Canada · France - available
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
This program offers a new medicine called zidesamtinib to adult patients in the UK with advanced ROS1-positive lung cancer or other ROS1-positive cancers. It's for those who have tried other treatments, can't join a regular trial, and have few other options available.
United States · Australia · Belgium - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - recruitingPHASE2
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
This study is testing a new drug, pumitamig, with chemotherapy (docetaxel) for advanced non-small cell lung cancer that has worsened after previous treatment. It aims to check the safety and how well the combination works.
United States · Australia · South Korea - active not recruitingPHASE2
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
This study is testing a new medicine called telisotuzumab vedotin for people with a specific type of advanced non-small cell lung cancer where a protein called c-Met is present. It aims to find out who benefits most and how well it works.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
This study is testing a new drug, TUB-040, for ovarian cancer and a type of lung cancer (non-small cell lung cancer) when standard treatments haven't worked. It checks how safe it is, how it moves in the body, and if it helps shrink tumours. The study aims to find the best dose.
United States · Belgium · Germany - recruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
United States · Argentina · Australia - active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Argentina · Austria · Belgium - recruitingPHASE1
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
This study is testing a new cancer medicine, OVM-200, for the first time in people. It involves up to 52 patients with prostate, lung, or ovarian cancer to check if it's safe and how well it works. It's given as an injection under the skin.
United Kingdom - recruitingPHASE3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This study is testing a new combination of two medicines, calderasib and pembrolizumab, for a specific type of lung cancer. We want to see if this combination works better than current treatments for people with advanced non-small cell lung cancer that has a particular genetic change.
United States · Argentina · Australia - active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This study aims to see if adding the drug pembrolizumab to standard chemotherapy before and after surgery helps people with early-stage non-small cell lung cancer live longer and prevent the cancer from returning. It's a large study comparing this new approach with chemotherapy alone.
United States · Argentina · Australia - recruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
United States · Argentina · Australia - recruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
United States · Argentina · Belgium - active not recruitingPHASE3
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
This study looks at a drug called osimertinib for people with a certain type of early-stage lung cancer after surgery. We want to see if it helps prevent the cancer from coming back compared to a dummy drug (placebo).
United States · Argentina · Brazil - active not recruitingPHASE1, PHASE2
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This study is testing a new drug, BT5528, for advanced cancers like ovarian, lung, and breast cancer. We want to find a safe dose, understand side effects, and see how well it works, sometimes given with another drug called nivolumab.
United States · Belgium · South Korea - recruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
United States · Argentina · Australia - active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at a new drug, divarasib, for advanced lung cancer with a specific genetic change (KRAS G12C). It compares divarasib to existing treatments, sotorasib or adagrasib, to see how well they work and if they are safe.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
United States · Argentina · Australia - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China